Calaluce et al. BMC Cancer 2010, 10:126 http://www.biomedcentral.com/1471-2407/10/126 well as start up funds from University of Missouri. We wish to thank Dr. Michael McManus (UCSF, California) for his guidance with the lentiviral system. Author details 1Departments of Surgery, University of Missouri, One Hospital Drive, Columbia, Missouri 65212, USA. 2Health Management and Informatics, University of Missouri, 187 Galena Hall, Columbia, Missouri 65212, USA. 3Statistics, University of Missouri, 146 Middlebush Hall, Columbia, Missouri 65211, USA. 4Molecular Microbiology and Immunology, One Hospital Drive, Columbia, Missouri 65212, USA. 5Child Health, One Hospital Drive, University of Missouri, Columbia, Missouri 65212, USA. 6National Institute of Aging, 251 Bayview Boulevard, Baltimore, Maryland 21224, USA. Authors’ contributions UA supervised the study. RC planned the experiments, performed microarrays and wrote the paper. MMG generated and performed analyses on cell lines as well as quantitative RT-PCR experiments. JWD performed statistical analyses on microarray experiments. JDM assisted in analyses of cell lines. YK and MG planned and performed biotin pull-down experiments. All authors read and approved the final manuscript. Competing interests The authors declare that they have no competing interests. Received: 30 September 2009 Accepted: 6 April 2010 Published: 6 April 2010 References 1. Dietel M, Sers C: Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch 2006, 448(6):744-755. 2. Mischel PS, Cloughesy TF, Nelson SF: DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci 2004, 5(10):782-792. 3. Muss HB: Targeted therapy for metastatic breast cancer. N Engl J Med 2006, 355(26):2783-2785. 4. Gygi SP, Rochon Y, Franza BR, Aebersold R: Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999, 19(3):1720-1730. 5. Ideker T, Thorsson V, Ranish JA, Christmas R, Buhler J, Eng JK, Bumgarner R, Goodlett DR, Aebersold R, Hood L: Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 2001, 292(5518):929-934. 6. Khabar KS, Bakheet T, Williams BR: AU-rich transient response transcripts in the human genome: expressed sequence tag clustering and gene discovery approach. Genomics 2005, 85(2):165-175. 7. Khabar KS: The AU-rich transcriptome: more than interferons and cytokines, and its role in disease. J Interferon Cytokine Res 2005, 25(1):1-10. 8. Intine RV, Tenenbaum SA, Sakulich AL, Keene JD, Maraia RJ: Differential phosphorylation and subcellular localization of La RNPs associated with precursor tRNAs and translation-related mRNAs. Mol Cell 2003, 12(5):1301-1307. 9. Tenenbaum SA, Carson CC, Lager PJ, Keene JD: Identifying mRNA subsets in messenger ribonucleoprotein complexes by using cDNA arrays. Proc Natl Acad Sci USA 2000, 97(26):14085-14090. 10. Tenenbaum SA, Lager PJ, Carson CC, Keene JD: Ribonomics: identifying mRNA subsets in mRNP complexes using antibodies to RNA-binding proteins and genomic arrays. Methods 2002, 26(2):191-198. 11. Keene JD: Organizing mRNA export. Nat Genet 2003, 33(2):111-112. 12. Keene JD, Tenenbaum SA: Eukaryotic mRNPs may represent posttranscriptional operons. Mol Cell 2002, 9(6):1161-1167. 13. Gerber AP, Herschlag D, Brown PO: Extensive association of functionally and cytotopically related mRNAs with Puf family RNA-binding proteins in yeast. PLoS Biol 2004, 2(3):E79. 14. Grigull J, Mnaimneh S, Pootoolal J, Robinson MD, Hughes TR: Genome- wide analysis of mRNA stability using transcription inhibitors and microarrays reveals posttranscriptional control of ribosome biogenesis factors. Mol Cell Biol 2004, 24(12):5534-5547. 15. Hieronymus H, Silver PA: Genome-wide analysis of RNA-protein interactions illustrates specificity of the mRNA export machinery. Nat Genet 2003, 33(2):155-161. Page 14 of 15 16. Hieronymus H, Yu MC, Silver PA: Genome-wide mRNA surveillance is coupled to mRNA export. Genes Dev 2004, 18(21):2652-2662. 17. Rajasekhar VK, Holland EC: Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene 2004, 23(18):3248-3264. 18. Atasoy U, Watson J, Patel D, Keene JD: ELAV protein HuA (HuR) can redistribute between nucleus and cytoplasm and is upregulated during serum stimulation and T cell activation. J Cell Sci 1998, 111(Pt 21):3145-3156. 19. Fan XC, Steitz JA: Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. Embo J 1998, 17(12):3448-3460. 20. Ma WJ, Cheng S, Campbell C, Wright A, Furneaux H: Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J Biol Chem 1996, 271(14):8144-8151. 21. Meisner NC, Hackermuller J, Uhl V, Aszodi A, Jaritz M, Auer M: mRNA openers and closers: modulating AU-rich element-controlled mRNA stability by a molecular switch in mRNA secondary structure. Chembiochem 2004, 5(10):1432-1447. 22. Brennan CM, Steitz JA: HuR and mRNA stability. Cell Mol Life Sci 2001, 58(2):266-277. 23. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100(1):57-70. 24. Lopez de Silanes I, Lal A, Gorospe M: HuR: post-transcriptional paths to malignancy. RNA Biol 2005, 2(1):11-13. 25. Abdelmohsen K, Lal A, Kim HH, Gorospe M: Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle 2007, 6(11):1288-1292. 26. Abdelmohsen K, Pullmann R Jr, Lal A, Kim HH, Galban S, Yang X, Blethrow JD, Walker M, Shubert J, Gillespie DA, Furneaux H, Gorospe M: Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell 2007, 25(4):543-557. 27. Lal A, Kawai T, Yang X, Mazan-Mamczarz K, Gorospe M: Antiapoptotic function of RNA-binding protein HuR effected through prothymosin alpha. Embo J 2005, 24(10):1852-1862. 28. Lal A, Mazan-Mamczarz K, Kawai T, Yang X, Martindale JL, Gorospe M: Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J 2004, 23(15):3092-3102. 29. Levy AP: Hypoxic regulation of VEGF mRNA stability by RNA-binding proteins. Trends Cardiovasc Med 1998, 8(6):246-250. 30. Lopez de Silanes I, Zhan M, Lal A, Yang X, Gorospe M: Identification of a target RNA motif for RNA-binding protein HuR. Proc Natl Acad Sci USA 2004, 101(9):2987-2992. 31. Nabors LB, Gillespie GY, Harkins L, King PH: HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine- rich elements within the 3’ untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res 2001, 61(5):2154-2161. 32. Sheflin LG, Zou AP, Spaulding SW: Androgens regulate the binding of endogenous HuR to the AU-rich 3’UTRs of HIF-1alpha and EGF mRNA. Biochem Biophys Res Commun 2004, 322(2):644-651. 33. Tran H, Maurer F, Nagamine Y: Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol Cell Biol 2003, 23(20):7177-7188. 34. Wang W, Caldwell MC, Lin S, Furneaux H, Gorospe M: HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. EMBO J 2000, 19(10):2340-2350. 35. Wang W, Yang X, Cristofalo VJ, Holbrook NJ, Gorospe M: Loss of HuR is linked to reduced expression of proliferative genes during replicative senescence. Mol Cell Biol 2001, 21(17):5889-5898. 36. Denkert C, Weichert W, Winzer KJ, Muller BM, Noske A, Niesporek S, Kristiansen G, Guski H, Dietel M, Hauptmann S: Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res 2004, 10(16):5580-5586. 37. Heinonen M, Bono P, Narko K, Chang SH, Lundin J, Joensuu H, Furneaux H, Hla T, Haglund C, Ristimaki A: Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 2005, 65(6):2157-2161. 38. Heinonen M, Fagerholm R, Aaltonen K, Kilpivaara O, Aittomaki K, Blomqvist C, Heikkila P, Haglund C, Nevanlinna H, Ristimaki A: Prognostic